# MPIG6B

## Overview
The MPIG6B gene encodes the megakaryocyte and platelet inhibitory receptor G6b, a transmembrane protein that is a member of the immunoglobulin superfamily. This receptor plays a pivotal role in the regulation of platelet function and hemostasis by acting as an inhibitory receptor on megakaryocytes and platelets. G6b-B contains key structural motifs, including the immunoreceptor tyrosine-based inhibitory motif (ITIM) and the immunoreceptor tyrosine-based switch motif (ITSM), which are essential for its function in signal transduction. These motifs facilitate interactions with protein tyrosine phosphatases, such as SHP-1 and SHP-2, leading to the inhibition of platelet activation pathways. The receptor's activity is modulated by ligand interactions, including binding to heparan sulfate, which enhances its inhibitory signaling capabilities. Mutations in MPIG6B have been linked to hematological disorders, underscoring its clinical significance as a potential target for therapeutic interventions in conditions like thrombocytopenia and thrombosis (Senis2007A; Soriano2021Targeting).

## Structure


## Function
The MPIG6B gene encodes the G6b-B protein, a member of the immunoglobulin superfamily, which plays a crucial role in regulating platelet function and maintaining hemostatic balance. G6b-B is primarily expressed on megakaryocytes and platelets, where it functions as an inhibitory receptor. It contains a transmembrane domain and cytoplasmic motifs, including the immunoreceptor tyrosine-based inhibitory motif (ITIM) and the immunoreceptor tyrosine-based switch motif (ITSM), which are essential for its signaling capabilities (Senis2007A; Soriano2021Targeting).

In healthy cells, G6b-B is constitutively phosphorylated by Src family kinases, creating docking sites for the SH2 domains of protein tyrosine phosphatases SHP-1 and SHP-2. This interaction leads to the deactivation of tyrosine kinases such as Syk, thereby inhibiting downstream signaling pathways that would otherwise promote platelet activation (Soriano2021Targeting). G6b-B's inhibitory function is crucial for preventing excessive platelet activation and aggregation, thus maintaining the resting state of platelets and preventing thrombosis (Soriano2021Targeting).

The protein's activity is modulated by ligand binding, such as with heparan sulfate, which induces ectodomain dimerization and further phosphorylation, enhancing its inhibitory signaling (Soriano2021Targeting). This regulatory mechanism underscores G6b-B's role in maintaining platelet homeostasis and its potential as a therapeutic target for antithrombotic therapies.

## Clinical Significance
Mutations in the MPIG6B gene, also known as G6b, are associated with several hematological disorders. One notable condition is hereditary macrothrombocytopenia, an autosomal recessive disorder characterized by abnormally large platelets and reduced platelet counts, leading to variable bleeding phenotypes. This condition arises from impaired proplatelet formation due to non-functional MPIG6B, which is crucial for normal platelet production (Collins2021Advances).

In mice, the absence of the G6b-B receptor, encoded by MPIG6B, results in macrothrombocytopenia and aberrant platelet function. This is characterized by increased platelet turnover, reduced platelet counts, and enhanced platelet reactivity, leading to bleeding diathesis. The deficiency also causes increased shedding of platelet receptors and altered platelet function, contributing to the hematological abnormalities observed (Mazharian2012Mice).

In humans, a novel variant of the G6B gene has been linked to familial autosomal recessive thrombocytopenia and anemia. This mutation leads to defects in platelet production and other hematologic abnormalities, including reduced red blood cells and increased white blood cells. The mutation disrupts the interaction of the G6B protein with SHP-1 and SHP-2 phosphatases, which are involved in the negative regulation of cell signaling (Melhem2017Novel).

## Interactions
The MPIG6B gene encodes the G6b-B protein, which is involved in several key interactions that regulate platelet function. G6b-B is a transmembrane protein that contains immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and immunoreceptor tyrosine-based switch motifs (ITSMs), which are constitutively phosphorylated by Src family kinases (SFKs). These phosphorylated motifs serve as docking sites for the SH2 domains of cytoplasmic protein tyrosine phosphatases SHP-1 and SHP-2. The binding of these phosphatases to G6b-B leads to their activation, which in turn deactivates tyrosine kinases such as Syk, thereby modulating downstream signaling pathways (Soriano2021Targeting).

G6b-B is also known to interact with the tyrosine phosphatase SHP-1 in resting platelets, and this interaction increases with tyrosine phosphorylation upon platelet activation. This suggests that G6b-B may regulate platelet activation by ITAM receptors, such as the collagen receptor GPVI and the low-affinity immune receptor FcγRIIA, through its interaction with SHP-1 (Senis2007A). Additionally, G6b-B binds to extracellular matrix components like heparan sulfate and heparin, which induces ectodomain dimerization, although this does not lead to robust downstream signaling (Soriano2021Targeting).


## References


[1. (Soriano2021Targeting) Eva M Soriano Jerez, Jonathan M Gibbins, and Craig E Hughes. Targeting platelet inhibition receptors for novel therapies: pecam-1 and g6b-b. Platelets, 32(6):761–769, March 2021. URL: http://dx.doi.org/10.1080/09537104.2021.1882668, doi:10.1080/09537104.2021.1882668. This article has 13 citations and is from a peer-reviewed journal.](https://doi.org/10.1080/09537104.2021.1882668)

[2. (Mazharian2012Mice) Alexandra Mazharian, Ying-Jie Wang, Jun Mori, Danai Bem, Brenda Finney, Silke Heising, Paul Gissen, James G. White, Michael C. Berndt, Elizabeth E. Gardiner, Bernhard Nieswandt, Michael R. Douglas, Robert D. Campbell, Steve P. Watson, and Yotis A. Senis. Mice lacking the itim-containing receptor g6b-b exhibit macrothrombocytopenia and aberrant platelet function. Science Signaling, October 2012. URL: http://dx.doi.org/10.1126/scisignal.2002936, doi:10.1126/scisignal.2002936. This article has 66 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1126/scisignal.2002936)

[3. (Collins2021Advances) Janine Collins, William J. Astle, Karyn Megy, Andrew D. Mumford, and Dragana Vuckovic. Advances in understanding the pathogenesis of hereditary macrothrombocytopenia. British Journal of Haematology, 195(1):25–45, March 2021. URL: http://dx.doi.org/10.1111/bjh.17409, doi:10.1111/bjh.17409. This article has 11 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1111/bjh.17409)

[4. (Senis2007A) Yotis A. Senis, Michael G. Tomlinson, Ángel García, Stephanie Dumon, Victoria L. Heath, John Herbert, Stephen P. Cobbold, Jennifer C. Spalton, Sinem Ayman, Robin Antrobus, Nicole Zitzmann, Roy Bicknell, Jon Frampton, Kalwant S. Authi, Ashley Martin, Michael J.O. Wakelam, and Stephen P. Watson. A comprehensive proteomics and genomics analysis reveals novel transmembrane proteins in human platelets and mouse megakaryocytes including g6b-b, a novel immunoreceptor tyrosine-based inhibitory motif protein. Molecular &amp; Cellular Proteomics, 6(3):548–564, March 2007. URL: http://dx.doi.org/10.1074/mcp.d600007-mcp200, doi:10.1074/mcp.d600007-mcp200. This article has 136 citations.](https://doi.org/10.1074/mcp.d600007-mcp200)

[5. (Melhem2017Novel) Motasem Melhem, Mohamed Abu‐Farha, Dinu Antony, Ashraf Al Madhoun, Chiara Bacchelli, Fadi Alkayal, Irina AlKhairi, Sumi John, Mohamad Alomari, Phillip L. Beales, and Osama Alsmadi. Novel g6b gene variant causes familial autosomal recessive thrombocytopenia and anemia. European Journal of Haematology, 98(3):218–227, January 2017. URL: http://dx.doi.org/10.1111/ejh.12819, doi:10.1111/ejh.12819. This article has 28 citations and is from a peer-reviewed journal.](https://doi.org/10.1111/ejh.12819)